PKF115-584 was also thoroughly characterized in a pre-clinical MM study by Sukhdeo et al. This compound was found to reduce β-catenin-LEF/TCF transcriptional activity and Wnt target gene expression, disrupts cell proliferation and induces cytotoxicity in HMCLs and primary PC isolates of MM patients. The gene discussed is HNF4A; the disease is Miyoshi myopathy.